Results 21 to 30 of about 81,406 (283)
SHOC2 mediates the drug-resistance of triple-negative breast cancer cells to everolimus
Cancer Biology & Therapy, 2023 Aberrant activation of the mTOR pathway is a characteristic alteration in triple-negative breast cancer, but the mTOR pathway inhibitor everolimus is not effective for the triple-negative breast cancer (TNBC) patients.
Wenwen Geng +4 more
doaj +1 more source
Robust Identification of Target Genes and Outliers in Triple-negative Breast Cancer Data [PDF]
, 2018 Correct classification of breast cancer sub-types is of high importance as it directly affects the therapeutic options. We focus on triple-negative breast cancer (TNBC) which has the worst prognosis among breast cancer types.
Casimiro, Sandra +4 more
core +2 more sources
High MYC mRNA expression is more clinically relevant than MYC DNA amplification in triple-negative breast cancer [PDF]
, 2019 DNA abnormalities are used in inclusion criteria of clinical trials for treatments with specific targeted molecules. MYC is one of the most powerful oncogenes and is known to be associated with triple-negative breast cancer (TNBC).
Dasgupta, Subhamoy +6 more
core +2 more sources
Drug Delivery, 2018 Gambogic acid (GA) is a naturally derived potent anticancer agent with extremely poor biocompatibility. In the present study, a novel of redox/pH dual-responsive multifunctional magnetic complex micelle (sPEG/HA/CSO-SS-Hex/Fe3O4/GA), which consisted of a
Mang Mang Sang +10 more
doaj +1 more source
Clinical and Experimental Obstetrics & Gynecology, 2023 Background: The population of older women (≥70 years old) with triple-negative breast cancer (TNBC) is increasing, but there are few prognostic studies for these patients.
Chongwu He +7 more
doaj +1 more source
PD-L1 expression in triple-negative breast cancer: a cross-sectional study in a Polish population
Polish Journal of Pathology, 2021 Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast carcinomas and represents an aggressive variant with a high mortality rate. PD-L1 is a protein that plays a pivotal role in suppressing the adaptive immune system.
Łukasz Szylberg +8 more
doaj +1 more source
The SOX11 transcription factor is a critical regulator of basal-like breast cancer growth, invasion, and basal-like gene expression. [PDF]
, 2016 Basal-like breast cancers (BLBCs) are aggressive breast cancers associated with poor survival. Defining the key drivers of BLBC growth will allow identification of molecules for targeted therapy.
Brown, Powel H +6 more
core +5 more sources
Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay. [PDF]
, 2017 BackgroundGlucocorticoid receptor (GR) activity plays a role in many aspects of human physiology and may play a crucial role in chemotherapy resistance in a wide variety of solid tumors.
Block, Thaddeus S +4 more
core +2 more sources
Chemotherapy with ceramide in TNBC
Oncoscience, 2015 Metastasis remains the major cause of cancer-related mortality, and currently there is a lack of therapies to eliminate this risk. Therefore, it is of crucial interest to better understand this multi-step cellular process and find the best markers to identify patients who will develop early and distant relapse.
Legembre, Patrick +2 more
openaire +3 more sources
Molecular & Cellular Oncology, 2020 Lipid and cholesterol reprogramming are often observed in specific cancer subtypes. We find that triple-negative breast cancers (TNBCs), but not estrogen receptor-positive (ER+) ones, adopt nuclear receptor RAR-related orphan receptor γ (RORγ) as their ...
Demin Cai, Xiong Zhang, Hong-Wu Chen
doaj +1 more source